Cooperative Agreement 2406662
Award Date
8/15/24
Completion Date
7/31/26
Dollars Obligated
$1M
Federal Agency
National Science Foundation
Awardee
Vcreate, Inc. (TDGANH2K4J93)
Federal Grant Program
47.084
Assistance Type
Cooperative Agreement
Place of Performance
Menlo Park, CA 94025, USA
Similar Awards
This Cooperative Agreement award from the National Science Foundation (NSF), under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program, provides $1,250,000 in funding to Rattan Life Science Inc., a self-certified small disadvantaged business, for the development and validation of a novel platform technology to enable the scalable generation of high-quality, tumor-targeted induced naïve T cells for off-the-shelf cancer immunotherapies. The project aims to increase the...
Vcreate, Inc. was awarded a $256,000 Project Grant from the National Science Foundation under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084) to develop a high-throughput platform for discovering T-cell receptor (TCR) based immunotherapies for late-stage cancer patients. The platform aims to screen thousands of TCRs against thousands of cancer antigens to identify clinically relevant TCRs that could serve as the basis for new treatments against currently incurable cancers....
This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), provides $414,803 to the Massachusetts Institute of Technology (MIT) to develop a new engineering strategy for improving the antigen sensitivity of T cell receptors (TCRs) used in TCR-T cell cancer immunotherapies. The project aims to implement high-throughput library screens of TCR constant region variants to identify mutations that can enhance TCR signaling...
This Cooperative Agreement award from the National Science Foundation (CFDA 47.084 - NSF Technology, Innovation, and Partnerships) provides $1,000,000.00 in funding to Window Therapeutics, Inc. to develop a novel class of antibody-drug conjugates (ADCs) for treating metastatic cancer. The project aims to significantly increase the drug-to-antibody ratio of ADCs, allowing for the use of less toxic, yet more effective, cancer-killing drugs to be delivered directly to tumor cells. The goal is to...
This SBIR Phase I award from the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $273,550 to Biocognon LLC for the development of a combinatorial platform to discover improved molecular recognition components for use in therapeutic and diagnostic antibodies. The project aims to utilize synthetic biology, next-generation DNA sequencing, and computational biology to efficiently generate and screen libraries of antibody...
This Project Grant award, valued at $574,808, was provided by the National Science Foundation (NSF) through its Engineering program (CFDA 47.041) to Duke University. The project aims to investigate the origins of cellular heterogeneity in T cells, which are critical for immune system function and have applications in cancer therapies like CAR T-cell therapy. The research will leverage advanced technologies, including spatial proteomic multiplexed imaging, in vitro cell tracking, and engineered...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $274,991 to Saber Therapeutics, Inc. will support the development of a new approach to deliver cancer-killing proteins specifically to acute myeloid leukemia (AML) cells while sparing healthy cells. The project aims to engineer natural killer (NK) cells with targeted protein degraders (TPDs) against three common AML driver proteins. The resulting NK-TPD cells will be tested for...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the development of a CD4 TCR-engineered T cell immunotherapy for the treatment of triple-negative breast cancer (TNBC). The award of $1,001,029.00 will fund the generation of a GMP-grade master cell bank and viral particles for the IMT-422 (CD4 TCR-STEM T cells) product, as well as the determination of its pharmacokinetics, biodistribution, and toxicity. This work aims to accelerate the...
This $353,204 Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) supports the development of a novel technology called Cell-MAPP by Pumpkinseed Technologies Inc., a for-profit company located in Palo Alto, California. The goal of this Phase I Small Business Innovation Research (SBIR) project is to demonstrate and advance Cell-MAPP, a live-cell monitoring system that enables continuous, high-throughput analysis of T cell states...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $275,000 to Covalabio Inc. supports the development of cell-penetrating monobodies as a new pharmaceutical intervention for treating certain cancers. The project aims to validate the cell-penetrating monobody technology by designing potent and selective inhibitors targeting oncogenic KRAS mutations in lung, pancreatic, and colorectal cancers. Key technical objectives include...